Y-mAbs Q2 Loss Widens to $25.6M Amid Rising R&D Costs

TL;DR

Y-mAbs' widening losses and legal woes make it a risky bet; stay away until they show a clear path to profitability or significant pipeline progress.

AI Summary

Y-mAbs Therapeutics, Inc. reported a net loss of $25.6 million for the three months ended June 30, 2025, compared to a net loss of $24.8 million for the same period in 2024, representing a 3.2% increase in loss. Research and development expenses were $25.6 million for the second quarter of 2025, up from $24.8 million in the second quarter of 2024. The company recognized $2.56 million in selling, general, and administrative expenses related to a shareholder lawsuit filed in February 2023 for the three months ended June 30, 2024. A significant subsequent event occurred on August 4, 2025, with the company entering into a license agreement with Stark International Lux. The company also has ongoing lease arrangements for its corporate headquarters in New Jersey, expiring by September 30, 2024, and a laboratory in New Jersey, expiring by February 1, 2025, with a forecast for a new laboratory lease extending to February 1, 2026. Share-based compensation awards, specifically Restricted Stock Units (RSUs) for performance, were outstanding as of June 30, 2025, across two tranches. The company's strategic outlook includes managing these lease expirations and continuing its research and development efforts despite increasing losses.

Why It Matters

Y-mAbs Therapeutics' widening net loss to $25.6 million and increased R&D expenses are critical for investors, signaling continued cash burn in a highly competitive biotech landscape. The ongoing shareholder lawsuit, incurring $2.56 million in SG&A expenses, adds a layer of legal and financial uncertainty, potentially diverting resources from core drug development. For employees, this financial pressure could impact job security and future growth opportunities. Customers, primarily patients awaiting new therapies, depend on the company's ability to sustain its research, making these financial results a bellwether for future product pipeline progress. The subsequent license agreement with Stark International Lux could offer a future revenue stream, but its impact is yet to be realized.

Risk Assessment

Risk Level: high — The company reported a net loss of $25.6 million for Q2 2025, an increase from $24.8 million in Q2 2024, indicating a worsening financial position. Additionally, $2.56 million in selling, general, and administrative expenses were incurred due to a shareholder lawsuit, adding legal and financial uncertainty.

Analyst Insight

Investors should exercise extreme caution and consider divesting or avoiding Y-mAbs Therapeutics shares given the increasing net losses and ongoing legal expenses. Monitor the impact of the Stark International Lux license agreement and future clinical trial results for any potential turnaround.

Key Numbers

• $25.6 million — Net Loss (for the three months ended June 30, 2025, an increase from $24.8 million in Q2 2024)
• $24.8 million — Net Loss (for the three months ended June 30, 2024)
• $25.6 million — Research and Development Expense (for the three months ended June 30, 2025)
• $2.56 million — Selling, General and Administrative Expenses (related to a shareholder lawsuit for the three months ended June 30, 2024)
• 3.2% — Increase in Net Loss (from Q2 2024 to Q2 2025)
• August 4, 2025 — Date of License Agreement (with Stark International Lux)
• September 30, 2024 — Lease Expiration (for corporate headquarters in New Jersey)
• February 1, 2025 — Lease Expiration (for laboratory in New Jersey)

Key Players & Entities

• Y-mAbs Therapeutics, Inc. (company) — filer of the 10-Q
• Stark International Lux (company) — party to a subsequent license agreement on August 4, 2025
• 03 Life Sciences (company) — organization name associated with the filer
• Bloomberg (company) — publisher of this analysis
• SEC (regulator) — regulator for 10-Q filings

FAQ

Risk Factors

• Shareholder Lawsuit [medium — legal]: The company incurred $2.56 million in selling, general, and administrative expenses related to a shareholder lawsuit filed in February 2023. This ongoing legal matter represents a financial and operational risk.
• Lease Expirations [medium — operational]: The corporate headquarters lease in New Jersey expires on September 30, 2024, and the laboratory lease expires on February 1, 2025. The company is forecasting a new laboratory lease extending to February 1, 2026, indicating potential disruption and costs associated with relocation or renewal.
• Increasing Net Loss [high — financial]: Y-mAbs reported a net loss of $25.6 million for Q2 2025, an increase from $24.8 million in Q2 2024, representing a 3.2% rise in losses. This trend, coupled with high R&D expenses, signals continued financial strain.
• Drug Development and Approval [high — regulatory]: As a biotechnology company, Y-mAbs is subject to stringent regulatory oversight from bodies like the FDA. Delays or failures in clinical trials or regulatory approvals for its drug candidates can significantly impact financial performance and market position.

Industry Context

Y-mAbs Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing antibody-based therapies for cancer. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often hinges on innovation, successful clinical trials, and securing strategic partnerships or funding to advance drug candidates through development and commercialization.

Regulatory Implications

As a biopharmaceutical company, Y-mAbs is subject to rigorous oversight by regulatory bodies such as the FDA. The development and approval process for new drugs is lengthy and costly, with potential for setbacks. Compliance with evolving regulations and successful navigation of clinical trial requirements are critical for market access and commercial viability.

What Investors Should Do

1. Monitor the financial impact of the Stark International Lux license agreement.
2. Analyze the company's strategy for managing increasing net losses and R&D expenses.
3. Assess the company's plan for lease expirations.

Key Dates

• 2024-09-30: Corporate headquarters lease expiration — Requires the company to secure new office space or renew its current lease, potentially impacting operational continuity and incurring new costs.
• 2025-02-01: Laboratory lease expiration — Necessitates securing new laboratory facilities or renewing the existing lease, crucial for ongoing research and development activities.
• 2025-08-04: License agreement with Stark International Lux — A significant subsequent event that could represent a new revenue stream or strategic partnership, the terms of which will be critical for future financial impact.

Glossary

Restricted Stock Units (RSUs)

A form of equity-based compensation where employees receive shares of stock after a vesting period. Performance RSUs are tied to specific company or individual performance metrics. (Indicates a component of executive and employee compensation, impacting future share dilution and operating expenses.)

Subsequent Event

A significant event that occurs after the balance sheet date but before the financial statements are issued or made available to users. (The license agreement with Stark International Lux is a material event that occurred after the reporting period and could have a significant impact on the company's future financial condition.)

Selling, General and Administrative Expenses (SG&A)

Costs incurred by a company that are not directly related to the production or procurement of goods or services, including marketing, salaries, and legal fees. (The $2.56 million in SG&A related to the shareholder lawsuit highlights a specific legal cost impacting the company's profitability.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Y-mAbs Therapeutics has experienced an increase in its net loss, rising by 3.2% to $25.6 million for the three months ended June 30, 2025. Research and development expenses remain a significant cost driver, mirroring the net loss figures. While specific revenue figures are not detailed in the provided context, the increasing net loss suggests a challenging revenue generation environment or escalating operational costs relative to income.

Key Financial Figures

• $0.0001 — e on which registered: Common Stock , $0.0001 par value YMAB Nasdaq Global Select

Filing Documents

• ymab-20250630x10q.htm (10-Q) — 2376KB
• ymab-20250630xex31d1.htm (EX-31.1) — 15KB
• ymab-20250630xex31d2.htm (EX-31.2) — 15KB
• ymab-20250630xex32d1.htm (EX-32.1) — 8KB
• ymab-20250630xex32d2.htm (EX-32.2) — 8KB
• 0001558370-25-010848.txt ( ) — 11052KB
• ymab-20250630.xsd (EX-101.SCH) — 67KB
• ymab-20250630_cal.xml (EX-101.CAL) — 56KB
• ymab-20250630_def.xml (EX-101.DEF) — 286KB
• ymab-20250630_lab.xml (EX-101.LAB) — 544KB
• ymab-20250630_pre.xml (EX-101.PRE) — 467KB
• ymab-20250630x10q_htm.xml (XML) — 2464KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our business strategy, future operations and results thereof, future financial position, future revenue, projected costs, prospects, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management, expected market growth and future results of current and anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "contemplate," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Decemb

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Item 1. Consolidated Financial Statements: 6 Consolidated Balance Sheets (unaudited) as of June 30, 2025 and December 31, 2024 6 Consolidated Statements of Net Loss and Comprehensive Loss (unaudited) for the three and six months ended June 30, 2025 and 2024 7 Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the three and six months ended June 30, 2025 and 2024 8 Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2025 and 2024 9

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 47 Item 4.

Controls and Procedures

Controls and Procedures 48

— OTHER INFORMATION

PART II — OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 48 Item 1A.

Risk Factors

Risk Factors 48 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53 Item 3. Defaults Upon Senior Securities 53 Item 4. Mine Safety Disclosures 53 Item 5. Other Information 53 Item 6. Exhibits 53 You should read this Quarterly Report and the documents we have filed as exhibits to this Quarterly Report completely and with the understanding that our actual future results may be materially different from the plans, intentions, and expectations disclosed in the forward-looking statements we may make. 5 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Consolidated Financial Statements

Item 1. Consolidated Financial Statements Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) June 30, December 31, 2025 2024 ASSETS CURRENT ASSETS Cash and cash equivalents $ 62,293 $ 67,234 Accounts receivable, net 15,740 19,688 Inventories 9,719 7,214 Other current assets 4,035 4,373 Total current assets 91,787 98,509 Property and equipment, net 269 42 Operating lease right-of-use assets 3,109 817 Intangible assets, net 2,177 2,276 Inventories, long-term 19,223 17,772 Other assets 646 488 TOTAL ASSETS $ 117,211 $ 119,904 LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES Accounts payable $ 7,571 $ 6,662 Accrued liabilities 14,888 16,406 Operating lease liabilities, current portion 486 630 Total current liabilities 22,945 23,698 Accrued milestones 3,200 3,200 Operating lease liabilities, long-term portion 2,638 190 Other liabilities 935 812 TOTAL LIABILITIES 29,718 27,900 Commitments and contingencies (Note 9) STOCKHOLDERS' EQUITY Preferred stock, $ 0.0001 par value, 5,500,000 shares authorized and none issued at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value, 100,000,000 shares authorized at June 30, 2025 and December 31, 2024; 45,438,420 and 44,988,313 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 5 4 Additional paid-in capital 583,671 576,872 Accumulated other comprehensive income ( 612 ) 2,264 Accumulated deficit ( 495,571 ) ( 487,136 ) TOTAL STOCKHOLDERS' EQUITY 87,493 92,004 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 117,211 $ 119,904 The accompanying notes are an integral part of the consolidated financial statements 6 Table of Contents Y-MABS THERAPEUTICS, INC. Consolidated Statements of Net Loss and Comprehensive Loss (unaudited) (In thousands, except share and per sha

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) NOTE 1—ORGANIZATION AND DESCRIPTION OF BUSINESS Y-mAbs Therapeutics, Inc. ("we," "us," "our," the "Company," or "Y-mAbs") is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy, and commercial stage antibody-based therapeutic products for the treatment of cancer. Y-mAbs is leveraging the Company's proprietary radioimmunotherapy and the antibody platforms, and the Company's deep expertise in the field of radioimmunotherapy and antibodies to develop a broad portfolio of innovative medicines largely in the space of pretargeted radio-isotope labeled therapeutics. The Company's broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. Y-mAbs operates as two business units – DANYELZA and Radioimmunotherapy ("RIT"). The Company is headquartered in New Jersey and was incorporated on April 30, 2015 under the laws of the State of Delaware. On August 4, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Yosemite Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), and solely for purposes of Section 5.16 and Article 8 thereof, Stark International Lux, a Luxembourg private limited liability company ( socit responsabilit limite ) ("Ultimate Parent"). Please refer to Note 16—SUBSEQUENT EVENTS for more information. NOTE 2—BASIS OF PRESENTATION The Company has incurred losses in every year since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development; technological uncertainty;

View Full Filing

View this 10-Q filing on SEC EDGAR